Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers

• Main Authors: Ruijia Chen (Author), Yalan Zhang (Author), Kongying Lin (Author), Defu Huang (Author), MaoJin You (Author), Yanjin Lai (Author), Jinye Wang (Author), Yingying Hu (Author), Na Li (Author)
• Format: Bog
• Udgivet: Frontiers Media S.A., 2022-07-01T00:00:00Z.
• Fag: article
• Online adgang: Connect to this object online.

Background: In the first-line treatment of biliary tract cancers (BTCs), XELOX (capecitabine plus oxaliplatin) showed comparable clinical efficacy and safety to gemcitabine and oxaliplatin (GEMOX), with fewer visits and better treatment management. Our study aims to investigate the cost-effectivenes...